GT Biopharma repositions Dr. Miller as Consulting Senior Medical Director for conflict-of-interest compliance

GT Biopharma, Inc.

Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.
He commenced as Consulting Senior Medical Director to align with University of Minnesota conflict-of-interest policies.
The change precedes the Phase I clinical trial of GTB-3650 compound at the University of Minnesota.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Jeffrey Miller

Consulting Senior Medical Director

GTBP · GT Biopharma, Inc.

Effective: 2024-09-16
Filed: September 16, 2024, 7:59 PM ET

Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jeffrey Miller changed role as Consulting Senior Medical Director at GT Biopharma, Inc..

Action: ceased serving as Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced as Consulting Senior Medical Director
Role: Consulting Senior Medical Director

Exact text from the filing

Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-036381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.